RSS   Newsletter   Contact   Advertise with us
Post Online Media

GSK director Moncef Slaoui to retire

GSKGSK announced that Moncef Slaoui, chairman of vaccines, has indicated to the board his intention to retire from the company on June 30, 2017.
Article continues below

READ MORE Intellia Therapeutics appoints two directors

Mr. Slaoui will remain a member of the Board until March 31, 2017. From April 1, 2017 until his retirement, he will serve as an advisor to both GSK and the Board.

Prior to his current role, Mr. Slaoui served as Chairman, GSK R&D for eight years. During his tenure at GSK, Mr. Slaoui has also had responsibility for the franchise commercial organisation, focused on new product launches and lifecycle management. He is a member of the Corporate Executive Team and Board of Directors.

Mr. Slaoui earned a PhD in Molecular Biology and Immunology from the Université Libre de Bruxelles, Belgium, and completed postdoctoral studies at Harvard Medical School and Tufts University School of Medicine, Boston. He was a professor of Immunology at the University of Mons, Belgium.

Mr. Slaoui has authored more than 100 scientific papers and presentations and is a member of the PhRMA Foundation Board of Directors, Advisory Board of Qatar Foundation, National Institutes of Health Advisory Committee to the Director, and the Biotechnology Industry Organization Board of Directors.

 LATEST MOVES FROM United Kingdom 


We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy